However, mutational frequencies vary between tumor types, with bladder cancer and sarcoma samples having the highest proportion of Rb1 mutations (20–25%), followed by prostate cancer, melanoma, and liver and brain cancer (10–15%). Here, RB1 is linked to neoplasm.